Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells
This study has been withdrawn prior to enrollment.
( New safety information reported in the post-marketing setting with efalizumab for treatment of chronic plaque psoriasis and trial conduct feasibility issues. )
Study NCT00777400
Information provided by University of California, San Francisco
First Received on October 20, 2008.
Last Updated on May 13, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
